OCULAR THERAPEUTIX, INCOCULEarnings & Financial Report
Ocular Therapeutix, Inc. is a biopharmaceutical firm specializing in developing and commercializing innovative ophthalmic therapies. Its products treat acute and chronic eye conditions including post-surgical pain, glaucoma, and dry eye, serving patients and ophthalmology providers primarily across the U.S. and select global markets.
OCUL Q4 FY2025 Key Financial Metrics
Revenue
$13.3M
Gross Profit
$11.7M
Operating Profit
$-69.8M
Net Profit
$-64.7M
Gross Margin
88.0%
Operating Margin
-526.5%
Net Margin
-488.0%
YoY Growth
-22.4%
EPS
$-0.27
OCULAR THERAPEUTIX, INC Q4 FY2025 Financial Summary
OCULAR THERAPEUTIX, INC reported revenue of $13.3M (down 22.4% YoY) for Q4 FY2025, with a net profit of $-64.7M (down 33.6% YoY) (-488.0% margin). Cost of goods sold was $1.6M, operating expenses totaled $81.4M.
Key Financial Metrics
| Total Revenue | $13.3M |
|---|---|
| Net Profit | $-64.7M |
| Gross Margin | 88.0% |
| Operating Margin | -526.5% |
| Report Period | Q4 FY2025 |
OCULAR THERAPEUTIX, INC Annual Revenue by Year
OCULAR THERAPEUTIX, INC annual revenue history includes year-by-year totals (for example, 2025 revenue was $52.0M).
OCULAR THERAPEUTIX, INC Quarterly Revenue & Net Profit History
OCULAR THERAPEUTIX, INC results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $13.3M | -22.4% | $-64.7M | -488.0% |
| Q3 FY2025 | $14.5M | -5.7% | $-69.4M | -477.3% |
| Q2 FY2025 | $13.5M | -18.1% | $-67.8M | -503.9% |
| Q1 FY2025 | $10.7M | -27.6% | $-64.1M | -598.7% |
| Q4 FY2024 | $17.1M | +15.4% | $-48.4M | -283.3% |
| Q3 FY2024 | $15.4M | +2.3% | $-36.5M | -236.6% |
| Q2 FY2024 | $16.4M | +8.3% | $-43.8M | -266.3% |
| Q1 FY2024 | $14.8M | +10.5% | $-64.8M | -438.9% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $14.8M | $16.4M | $15.4M | $17.1M | $10.7M | $13.5M | $14.5M | $13.3M |
| YoY Growth | 10.5% | 8.3% | 2.3% | 15.4% | -27.6% | -18.1% | -5.7% | -22.4% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $538.9M | $517.1M | $490.4M | $457.9M | $405.9M | $451.3M | $410.9M | $808.1M |
| Liabilities | $131.0M | $139.4M | $138.3M | $142.6M | $140.0M | $145.4M | $152.7M | $153.7M |
| Equity | $408.0M | $377.7M | $352.0M | $315.3M | $265.9M | $305.9M | $258.2M | $654.3M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-33.9M | $-24.8M | $-36.6M | $-39.4M | $-44.7M | $-55.2M | $-50.7M | $-54.2M |